Inducible CAR T Cell Therapy for Solid Tumors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cancer immunotherapy approaches, such as CAR T cell therapy and immune checkpoint blockade, face challenges in effectively targeting solid tumors due to limited T cell persistence and immunosuppressive microenvironments, leading to systemic toxicities and collateral damage to healthy tissues.
Innovation Solution
The integration of a cancer-inducible prodrug strategy with CAR T cell therapy and immune checkpoint blockade, utilizing chemically-induced proximity (CIP) technology and abscisic acid (ABA) prodrugs that become active only in solid tumor microenvironments, enabling targeted expression of therapeutic proteins like PD-L1 mAb and TRAIL within tumors while minimizing systemic effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If CAR T cell therapy is administered systemically, then T cell activity against tumors is enhanced, but systemic toxicities and collateral damage to healthy tissues occur
Solution Approach 1:
The patent applies local quality by making T cell activation conditional on tumor-specific microenvironmental cues. The T cells are engineered with inducible expression systems that remain dormant until exposed to tumor-specific signals (hypoxia, proteases, pH), thereby concentrating therapeutic activity locally at the tumor site while sparing healthy tissues from systemic toxicities
Solution Approach 2:
The patent uses tumor microenvironmental cues (hypoxia, proteases, pH) as intermediaries to trigger T cell activation. These cues act as mediators that translate tumor presence into selective T cell activation, enabling the T cells to distinguish between tumor and healthy tissues without requiring systemic administration of activating agents
2Reliability
If T cells are activated systemically, then tumor targeting is enhanced, but T cell persistence is limited
Solution Approach 1:
The patent applies preliminary action by pre-engineering T cells with inducible expression systems and tumor-specific receptors before administration. The T cells are prepared in an dormant but primed state, allowing them to persist in the body without activating until they encounter the tumor microenvironment, thereby extending persistence while maintaining targeted activation
Solution Approach 2:
The patent applies dynamics by creating T cells with switchable activation states. The inducible expression systems allow T cells to transition from a dormant, persistent state to an activated, tumor-killing state in response to tumor-specific cues, optimizing both persistence duration and tumor targeting efficacy throughout the therapeutic process
3Reliability
If therapeutic proteins are expressed continuously, then anti-tumor activity is maintained, but collateral damage to healthy tissues increases
Solution Approach 1:
The patent applies periodic action by making therapeutic protein expression pulsatile rather than continuous. The inducible expression systems trigger protein production only in response to tumor-specific microenvironmental cues, creating on-demand expression that maintains anti-tumor activity when needed while minimizing collateral damage during dormant periods in healthy tissues
Solution Approach 2:
The patent applies local quality by spatially restricting therapeutic protein expression to the tumor microenvironment. The inducible systems ensure that proteins are produced only where tumor-specific cues are present, concentrating anti-tumor activity at the target site while preventing collateral damage to healthy tissues that lack the activating cues
4Reliability
If prodrugs are activated by tumor microenvironmental cues, then therapeutic specificity is improved, but activation conditions must be precisely controlled
Solution Approach 1:
The patent applies self-service by engineering T cells to autonomously sense and respond to tumor microenvironmental cues without external control. The inducible expression systems are built into the T cells themselves, allowing them to self-activate when encountering tumor-specific signals, thereby achieving high therapeutic specificity while minimizing the complexity of external activation control systems
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach enhances T cell activity and persistence specifically within solid tumors, producing therapeutic proteins only when activated by tumor-specific cues, reducing collateral damage and improving therapeutic specificity and efficacy.
Implementation Method 1
A second exogenous polynucleotide encodes polypeptide components of a chemical induced proximity (CIP) complex. Presence of the inducer in the T cell induces assembly of the CIP expression system and expression of the therapeutic polypeptide.
Implementation Method 2
the regulatory region binds components of a chemical induced proximity (CIP) expression system
Implementation Method 3
A third exogenous polynucleotide that encodes a chimeric antigen receptor that specifically binds to an antigen expressed by cells of the tumor
Implementation Method 4
administering to the subject an inactive prodrug of the inducer, the inactive prodrug being activatable to the inducer by a tumor microenvironment-associated signal (e.g., a protease or hypoxia) within a solid tumor
Implementation Method 5
the inactive prodrug being activatable to the inducer by a tumor microenvironment-associated signal (e.g., a protease or hypoxia)
Data Source
AI summary
A modified T cell includes exogenous polynucleotides that encode components of a therapeutic expression system. A first exogenous polynucleotide encodes a therapeutic polypeptide operably linked to a regulatory region inducible by inducer. A second exogenous polynucleotide encodes polypeptide components of a chemical induced proximity (CIP) complex. A third exogenous polynucleotide that encodes a chimeric antigen receptor that specifically binds to an antigen.